Treating high-risk diabetic hypertensive patients with comorbid conditions

American Journal of Kidney Diseases

Volumn 36, Issue 3 SUPPL., 2000, Pages

  Schrier, R W ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Angiotensin II (Ang II); Angiotensin II receptor blockers (ARBs); Angiotensin converting enzyme (ACE) inhibitors; Diabetes mellitus; Diabetic nephropathy; End stage renal disease (ESRD); Hypertension; Valsartan

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VALSARTAN;

BLOOD PRESSURE REGULATION; COMORBIDITY; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; MICROVASCULATURE; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0033857858     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2000.9686     Document Type: Conference Paper

References (36)

1. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates, and projections
2. American Diabetes Association: Diabetes facts and figures
3. National estimates and general information on diabetes in the United States
4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
5. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy
6. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
8. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy
9. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy
10. Effects of long-term antihypertensive treatment on kidney function in diabetic nephropathy
11. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy
12. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
13. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
14. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension
15. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
16. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
17. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
18. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
19. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients
20. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study
21. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
22. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
23. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes
24. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM
25. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass
26. Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats
27. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonist
28. Prevention of renal injury in diabetic MWF rats by angiotensin II antagonism
29. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease
30. Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus
31. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: A placebo-controlled trial
32. Safety and efficacy of irbesartan in hypertensive patients with type II diabetes and proteinuria
33. ABCD-2V: Appropriate Blood Pressure Control in Diabetes - Part 2 With Valsartan
34. Multicenter collaborative trial of angiotensin II receptor antagonism on morbidity, mortality and renal function in hypertensive type II diabetic patients with nephropathy
35. Quality of life in patients with NIDDM and nephropathy at baseline: The losartan renal protection study (RENAAL)